Rhupus Syndrome and Efficacy of Etanercept Treatment

Yang Beibei

Status: Completed

Conditions: Rhupus Syndrome, Etanercept

Treatments: Drug: etanercept

Study type: Observational

Funder types: Other

Identifiers

NCT02766439

201233-004

Details and patient eligibility

About

between March 2013 and March 2014, Rhupus patients were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

Full description

between March 2013 and March 2014, patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) >5.1 were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

Enrollment: 6 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Rhupus patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) >5.1

Exclusion criteria

• those who had participated in other studies

Trial design

6 participants in 1 patient group

Rhupus syndrome, SLE without RA

Description:

Rhupus syndrome, SLE without RA

Treatment:

Drug: etanercept